FDA puts hold on BioCryst trial; ViveBio raises $4M;

Conversations on Twitter :

 @FierceBiotech: In case you missed it: Top 50 Industry Voices in Biotech Twittersphere -- 2012. Special Report | Follow @FierceBiotech

 @JohnCFierce: Updated Acadia story with CEO comments on pimavanserin dev plans. Confirm Ph3, pursue schizophrenia and Alzheimer's psychosis. Story | Follow @JohnCFierce

 @RyanMFierce: Why Big Data alone lacks the punch pharma needs. Article | Follow @RyanMFierce

> In the latest in a series of setbacks, BioCryst Pharmaceuticals ($BCRX) says the FDA has put a clinical hold on its development program for BCX4161 for hereditary angioedema. Regulators raised questions regarding investigators' compounding plans for the drug at clinical sites. SEC filing

> Arno Therapeutics has raised $12.7 million to back its work on onapristone and the AR-42 oncology therapeutic programs. Release

> ViveBio has reportedly raised most of a planned $4 million investment round. Story

> Cytokinetics ($CYTK) says it gained positive data from a recently completed Phase IIa study of tirasemtiv in patients with generalized myasthenia gravis. Release

Pharma News

@FiercePharma: Merck KGaA says it won't offload its consumer health unit, despite promise of big $$. Report | Follow @FiercePharma

> Abbott nabs new Humira use, launches Amitiza in Japan. News

> Sharpening Victoza's edge, Novo touts data in trial against Januvia, Byetta. More

Medical Device News

 @FierceMedDev: New special report: Top 10 Diagnostics Companies 2012. Report | Follow @FierceMedDev

@MarkHFierce: Venture funding lives: TriReme Medical pulled in $18 million in a new round. Release | Follow @MarkHFierce

 @DamianFierce: As Mindray Medical knows, being a Chinese company gives you cost advantages but can come with some PR hurdles. More | Follow @DamianFierce

> India's Trivitron expands Dx reach with $20.4M buy. Article

> Merit buys GE unit for $167M. News

Pharma Manufacturing News

> Some 'misbranded drugs' turned up in Avastin probe came from Roche plant. News

> Switzerland, home of Roche and Novartis, gets pass from EU API rule. Story

> EMA wants manufacturers to offer up drug shortage 'risk analysis'. Article

> Novartis gets FDA OK for faster flu vaccine production at U.S. plant. More

Biotech Research News

> German team combines 2 old drugs for new MS treatment. More

> Stem cell-reliant HIV vaccine launches animal studies in January. Article

> Anti-cancer virus could gain new power with patient immune cell tweak. Story

> McGill scientists link autistic behavior to brain protein mutation. Item

And Finally… A research team at Kansas State University has set out to see if the right kind of social media campaign can help stop the spread of disease. Some people get most of their information from Facebook these days, making social media a big player in educating consumers. Release

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.